Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
CD55 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
| Primary Accession | P08174 |
|---|---|
| Clone Names | 100427061 |
| Gene ID | 1604 |
|---|---|
| Other Names | Complement decay-accelerating factor, CD55, CD55, CR, DAF |
| Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
| Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
| Name | CD55 |
|---|---|
| Synonyms | CR, DAF |
| Function | This protein recognizes C4b and C3b fragments that condense with cell-surface hydroxyl or amino groups when nascent C4b and C3b are locally generated during C4 and c3 activation. Interaction of daf with cell-associated C4b and C3b polypeptides interferes with their ability to catalyze the conversion of C2 and factor B to enzymatically active C2a and Bb and thereby prevents the formation of C4b2a and C3bBb, the amplification convertases of the complement cascade (PubMed:7525274). Inhibits complement activation by destabilizing and preventing the formation of C3 and C5 convertases, which prevents complement damage (PubMed:28657829). |
| Cellular Location | [Isoform 1]: Cell membrane; Single-pass type I membrane protein [Isoform 3]: Secreted [Isoform 5]: Secreted [Isoform 7]: Cell membrane; Lipid-anchor, GPI-anchor |
| Tissue Location | Expressed on the plasma membranes of all cell types that are in intimate contact with plasma complement proteins. It is also found on the surfaces of epithelial cells lining extracellular compartments, and variants of the molecule are present in body fluids and in extracellular matrix |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes a protein involved in the regulation ofthe complement cascade. The encoded glycoprotein is also known asthe decay-accelerating factor (DAF); binding of DAF to complementproteins accelerates their decay, disrupting the cascade andpreventing damage to host cells. Antigens present on the DAFglycoprotein constitute the Cromer blood group system (CROM). Twoalternatively spliced transcripts encoding different proteins havebeen identified. The predominant transcript encodes amembrane-bound protein expressed on cells exposed to plasmacomponent proteins but an alternatively spliced transcript producesa soluble protein present at much lower levels. Additional,alternatively spliced transcript variants have been described, buttheir biological validity has not been determined. [provided byRefSeq].
References
Romero, R., et al. Am. J. Obstet. Gynecol. 203 (4), 361 (2010) :Gustafsson, D.J., et al. Virology 405(2):474-482(2010)Alegretti, A.P., et al. Cell. Immunol. 265(2):127-132(2010)Kim, Y., et al. Ann. Clin. Lab. Sci. 40(3):226-232(2010)Storry, J.R., et al. Transfusion 43(3):340-344(2003)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
